Browse the evidence

Combining GLP-1RA therapy with resistance exercise and high protein intake preserves fat-free mass better than GLP-1RA therapy alone in older adults with obesity.

To get the most benefit from GLP-1 medications without losing muscle, you must also do resistance exercise (like weights) at least twice a week and eat enough protein (1.0-1.2g per kg of body weight). This combination helps you lose fat while keeping your strength.

High-quality weight loss, defined as maximizing fat loss while preserving skeletal muscle mass, is critical for maintaining metabolic health, insulin sensitivity, and long-term weight maintenance.

When losing weight, prioritize strategies that protect your muscles, such as adequate protein intake and resistance exercise. Losing muscle along with fat can harm your metabolism and insulin sensitivity, making long-term weight maintenance harder.

Resistance exercise combined with caloric restriction is the most effective non-pharmacological strategy for preserving skeletal muscle mass and strength during weight loss.

Do not rely on diet alone. Incorporate resistance training into your weight loss plan to prevent muscle loss and maintain strength.

Obesity is a modifiable risk factor for pancreatic cancer (PC), with a 5-unit BMI increase associated with an 8-12% rise in PC risk.

Maintaining a healthy weight, especially around the abdomen, is important for reducing your risk of pancreatic cancer. Obesity is linked to an 8-12% increase in risk for every 5-unit increase in BMI.

Intensive, multicomponent lifestyle intervention (diet, exercise, behavioral counseling) remains foundational and synergistic with anti-obesity medications (GLP-1 RAs), improving outcomes and mitigating side effects, whereas relying on medication alone without lifestyle support may lead to suboptimal results and higher discontinuation.

Do not skip lifestyle changes just because you are taking weight-loss medication. Combine your medication with a structured plan involving diet, exercise, and behavioral counseling. This approach maximizes your weight loss, helps you keep the weight off, and can reduce medication side effects like nausea. Aim for 200-300 minutes of moderate exercise per week and attend intensive counseling sessions (at least 12 in the first year).

Weight reduction of 5-10% improves metabolic risk factors, while reduction of ≥10-15% consistently improves sleep apnea, reduces new-onset type 2 diabetes, and reduces overall mortality.

Aim for a 5-10% weight loss to improve metabolic markers, and 10-15% or more to significantly impact sleep apnea and mortality. Focus on sustainable energy balance rather than specific diet dogmas, as weight loss itself is the primary driver of remission for conditions like T2DM.

Physical activity of ≥5000 steps per day is a reasonable initial goal for obesity management, with ≥10,000 steps associated with greater weight reduction.

Start with 5000 steps per day. This is achievable and offers health benefits. If you can increase to 10,000 steps, you may see greater weight loss. Use walking as a tool for maintenance and metabolic health, not just calorie burning.

Weight loss of at least 5-10% significantly lowers systolic and diastolic blood pressure in obese individuals, and this effect is independent of the specific weight loss strategy used.

Achieving a 5-10% weight loss can significantly lower blood pressure (5-20 mmHg systolic). This benefit is achieved regardless of the method used (diet, exercise, or medication). Targeting at least 10% weight loss is recommended for most patients to see meaningful improvements in obesity-related complications.

Subcutaneous tirzepatide is the most cost-effective anti-obesity medication for adults without diabetes over a 68-week period, demonstrating superior incremental cost-effectiveness compared to oral semaglutide, subcutaneous semaglutide, and subcutaneous liraglutide.

For adults without diabetes seeking weight loss, subcutaneous tirzepatide offers the best value for money among current GLP-1 based therapies over a 68-week period. It is more cost-effective than oral semaglutide, subcutaneous semaglutide, and subcutaneous liraglutide. While oral semaglutide is a good alternative for those who dislike injections, tirzepatide provides superior cost-effectiveness. Patients should discuss these options with their healthcare provider, considering factors like injection preference, insurance coverage, and potential side effects.

GLP-1 receptor agonists (GLP-1 RAs) are effective for preoperative weight loss in orthopaedic surgery patients with obesity and type-2 diabetes, reducing surgical risk without increasing postoperative complications.

If you are having orthopaedic surgery and take GLP-1s (like Ozempic or Wegovy), tell your surgeon and anesthesiologist. You likely need to stop taking them a week before (for weekly doses) or on the day of (for daily doses) to prevent stomach issues during anesthesia. This helps ensure your surgery goes smoothly and reduces infection risk.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, provides superior glycemic control and weight loss compared to GLP-1 receptor agonists alone, while offering cardioprotective benefits through lipid lowering and anti-inflammatory mechanisms.

Tirzepatide is a once-weekly injection that activates two gut hormones (GIP and GLP-1) to lower blood sugar, reduce appetite, and protect the heart. It is more effective than older GLP-1 drugs for weight loss and blood sugar control. Start with a low dose to minimize stomach upset, and work with your doctor to find the right dose for you.

GLP-1 receptor agonists (e.g., semaglutide, tirzepatide) produce clinically significant weight loss (approx. 10-22%) but are associated with high rates of gastrointestinal adverse events.

GLP-1 medications like semaglutide and tirzepatide are highly effective for significant weight loss (10-22%+), but they come with notable gastrointestinal side effects. They are most effective when combined with lifestyle changes and psychological support, rather than used in isolation.

Consuming 20–40g of whey protein immediately after resistance exercise significantly increases myofibrillar fractional synthetic rate (FSR) and activates the AKT/mTOR signaling pathway (AKT, mTOR, 4E-BP1, p70S6K, rpS6) in healthy adults, thereby extending the post-exercise anabolic window.

For healthy adults engaging in resistance training, consuming 20-40g of whey protein around your workout (either immediately after or up to 45 minutes before) significantly boosts muscle protein synthesis compared to placebo. This strategy activates the AKT/mTOR pathway, which drives muscle repair and growth. You do not need to consume excessive amounts (>40g) to see benefits, and pre-workout consumption may even offer a slight edge in FSR magnitude for some protocols.

Post-exercise carbohydrate intake of approximately 1.2 g/kg body mass per hour for up to 4 hours is essential for restoring glycogen reserves, supporting immune system energy needs, and facilitating tissue repair.

After your workout, eat about 1.2 grams of carbohydrates for every kilogram of your body weight each hour for the next 4 hours. For example, if you weigh 70kg, aim for 84g of carbs per hour. This helps refill your energy stores and supports your immune system. Don't fear carbs here; they are essential for recovery.

Post-exercise ingestion of high-quality protein (0.3–0.5 g/kg body mass) stimulates net muscle protein anabolism and contributes to faster tissue growth and repair.

After your workout, consume 0.3 to 0.5 grams of high-quality protein for every kilogram of your body weight. For a 70kg person, this is 21-35g of protein. This helps build and repair muscle tissue.

Pre-sleep nutrition, specifically casein- or protein-rich meals with slow digestion rates, has a restorative effect on the musculoskeletal, endocrine, immune, and nervous systems.

Eat a slow-digesting protein source, like casein or Greek yogurt, before bed. This helps your body recover and repair tissues while you sleep. Don't worry about fat gain if your total daily calories are on track.

Limited walking frequency (less than 1 day per week) significantly increases the odds of hypertension and diabetes, with the risk being more pronounced in socioeconomically vulnerable populations.

Walking less than once a week significantly increases your risk of high blood pressure and diabetes, especially if you have limited income. Aim to walk at least a few days a week to reduce these risks, as consistent walking is a powerful protective factor for older adults.

Patients treated with GLP-1 based therapies must increase protein intake to 1–1.5 g/kg bodyweight/day and engage in resistance training to mitigate the loss of lean body mass (LBM) and prevent sarcopenic obesity.

If you are taking a GLP-1 medication like Ozempic or Wegovy, you must eat more protein than the standard recommendation. Aim for 1 to 1.5 grams of protein per kilogram of your body weight every day. Additionally, you must lift weights or do resistance exercises at least twice a week. This combination is the only proven way to stop your body from eating its own muscle while you lose fat.

Whey protein supplementation (20-40 g/day) combined with resistance training preserves lean body mass and improves strength during GLP-1RA-induced weight loss.

Aim for 1.2-2.0 grams of protein per kilogram of body weight daily. Use whey protein shakes (20-40g) to help meet this goal, especially if you struggle to eat enough solid food. Combine this with resistance training to protect your muscles.

Omega-3 fatty acid supplementation (≥1 g/day) supports muscle quality, cardiovascular health, and reduces inflammation during GLP-1RA treatment.

Take at least 1 gram of Omega-3 fatty acids daily. This helps protect your heart, reduces inflammation, and may support muscle quality while you lose weight.

In patients with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis, achieving MASH resolution and fibrosis improvement is significantly associated with greater reductions in body weight, improved glycemic control (HbA1c), and normalization of liver fat.

If you have MASH with fibrosis, achieving significant weight loss, better blood sugar control, and normalizing liver fat are key steps toward resolving the disease. Tirzepatide, taken once weekly and titrated up from 2.5mg to 5-15mg over several months, has been shown to facilitate these metabolic changes, which in turn drive histological improvement in the liver.

Retatrutide (4-12 mg weekly) produces early, sustained changes in appetite and eating behaviors (reduced hunger, increased satiety, smaller portions) within 8 weeks, leading to significant weight loss and improved physical/emotional well-being in adults with obesity.

If you have obesity or overweight with health complications, retatrutide (4-12mg weekly) significantly reduces hunger and increases fullness within weeks, leading to substantial weight loss (up to 24%) and improved energy/mobility. It addresses the biological barriers to lifestyle changes that often cause failure with diet/exercise alone. Expect some frustration if results are slower than hoped or side effects occur, but the behavioral shift in eating is a key benefit.

Resistance training preserves or increases lean muscle mass and improves muscle quality in adults with obesity, even when combined with energy-restricted diets or obesity management medications that typically cause lean mass loss.

Incorporate resistance training into your routine to protect your muscle mass. This is especially important if you are dieting or taking weight-loss medications, as these can cause muscle loss. Focus on strength and function rather than just size.

Exercise training, particularly aerobic interval training and cardiac rehabilitation, is a Class I recommendation that counteracts skeletal muscle wasting and improves functional capacity in heart failure patients.

Engage in supervised exercise programs, such as cardiac rehabilitation or aerobic interval training. These are strongly recommended for heart failure patients to maintain muscle strength and improve how you feel.